News

Article

Subcutaneous Amycretin Yields Promising Weight Loss in Phase 1b/2a Trial

Author(s):

Key Takeaways

  • Amycretin, a GLP-1 and amylin receptor agonist, showed up to 22% weight loss over 36 weeks in a Phase 1b/2a trial.
  • The trial demonstrated a safety profile consistent with incretin-based therapies, with mild-to-moderate gastrointestinal adverse events.
SHOW MORE

Subcutaneous amycretin achieved up to a 22.0% weight loss over 36 weeks, with a consistent safety profile to other incretin-based therapies.

Subcutaneous Amycretin Yields Promising Weight Loss in Phase 1b/2a Trial | Image Credit: Novo Nordisk

Martin Holst Lange

Credit: Novo Nordisk

Topline data from a Phase 1b/2a clinical trial were positive for once-weekly subcutaneous amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor agonist intended for the treatment of overweight or obesity.1

Announced by Novo Nordisk on January 24, 2025, amycretin demonstrated a safety profile similar to other incretin-based therapies, with an estimated body weight loss of up to 22% over a total treatment duration of 36 weeks, if patients adhered to treatment.

“The results seen in the trial support the weight-lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation,” Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a statement.1

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development for adults with overweight or obesity and for adults with type 2 diabetes (T2D), with both subcutaneous and oral administration. Novo Nordisk previously released Phase 1 data from the oral amycretin program, demonstrating its use was associated with a mean reduction in body weight of –13% at 12 weeks among 16 patients with a mean baseline body weight of 89 kg.2

Across 5 parts, this randomized, placebo-controlled, and double-blinded study evaluated the safety, tolerability, pharmacokinetics, and proof-of-concept of subcutaneous amycretin administration in people with overweight or obesity. A single ascending dose (Part A) was assessed for pharmacokinetics and the starting dose for the first multiple-dose cohort. In the second part, the safety and tolerability of amycretin were determined using dose escalation until 36 weeks of treatment duration (Part B).1

In the proof-of-concept part of the trial, Novo Nordisk evaluated body weight loss for up to 36 weeks by escalating amycretin to levels of 1.25 mg, 5 mg, and 20 mg dosed for 12 weeks, respectively (Part E, D, and C). The primary endpoint of treatment-emergent adverse events (TEAEs) was assessed in 125 people with overweight or obesity.

Analysis showed a consistent safety profile with incretin-based therapies, with the most common adverse events being gastrointestinal and mild-to-moderate severity. Assessment of the treatment effects of amycretin, based on treatment adherence, revealed an estimated weight loss of 9.7% on the 1.25 mg (20 weeks), 16.2% on 5 mg (28 weeks), and 22.0% on 20 mg (36 weeks) doses from a mean baseline body weight of 92.7 kg.

On the other hand, those treated with placebo experienced an estimated 1.9%, 2.3%, and 2.0% body weight gain, respectively. Citing the positive effect of amycretin on weight loss, and its well-tolerated and consistent safety profile, Novo Nordisk announced plans for further clinical development of amycretin for overweight or obesity.

“We are very encouraged by the subcutaneous Phase 1b/2a results for amycretin in people living with overweight or obesity,” Lange added.1

References

  1. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. Novo Nordisk. January 24, 2025. Accessed January 24, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915251.
  2. Campbell P. Novo Nordisk delivers updates on development of semaglutide, CAGRISEMA, Amycretin, and more. HCP Live. March 7, 2024. Accessed January 24, 2025. https://www.hcplive.com/view/novo-nordisk-delivers-updates-on-development-of-semaglutide-cagrisema-amycretin-and-more.
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
© 2025 MJH Life Sciences

All rights reserved.